CG Oncology Inc. (CGON) vs PTC Therapeutics, Inc. (PTCT)
A side-by-side comparison of CG Oncology Inc. and PTC Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CGON
CG Oncology Inc.
$63.62HealthcareDelayed quote: Oct 6, 2026, 1:30 PM EDT
PTCT
PTC Therapeutics, Inc.
$63.23HealthcareDelayed quote: Oct 6, 2026, 1:25 PM EDT
Total return — CGON vs PTCT
growth of $100 · dividends reinvested · last 3yCGON +84.9% (+22.7%/yr)PTCT +133.4% (+32.6%/yr)PTCT compounded faster over this window
CGON PTCT
CGON vs PTCT: by the numbers
- •CGON is the larger company ($5.61B vs $5.28B market cap).
- •Both run net losses; PTCT's is the smaller (-3.80% vs -3602.68% net margin).
Metrics side by side
Valuation
| Metric | CGON | PTCT |
|---|---|---|
| Forward P/E | N/A | 49.76 |
| P/S ratio | 901.01 | 5.23 |
| P/B ratio | 5.45 | N/A |
| EV / EBITDA | N/A | 28.70 |
Profitability
| Metric | CGON | PTCT |
|---|---|---|
| Gross margin | -15.02% | 95.85% |
| Operating margin | -4722.13% | 49.49% |
| Net margin | -3602.68% | -3.80% |
| ROE | -21.80% | N/A |
| ROIC | -24.33% | 4.59% |
Growth (annualized)
| Metric | CGON | PTCT |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 16.41% |
| Total return CAGR (5Y) | N/A | 11.75% |
Go deeper
Dig into the metrics
CG Oncology ROEPTC Therapeutics ROECG Oncology operating marginPTC Therapeutics operating marginCG Oncology revenue growthPTC Therapeutics revenue growthCG Oncology free cash flowPTC Therapeutics free cash flow
CG Oncology & PTC Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.